Trial Outcomes & Findings for Non-cutting Laser Therapy in the Treatment of Acne (NCT NCT00113425)

NCT ID: NCT00113425

Last Updated: 2016-10-18

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

44 participants

Primary outcome timeframe

Baseline and Week 10

Results posted on

2016-10-18

Participant Flow

Participant milestones

Participant milestones
Measure
All Study Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Overall Study
STARTED
44
Overall Study
COMPLETED
29
Overall Study
NOT COMPLETED
15

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Non-cutting Laser Therapy in the Treatment of Acne

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treated Group Pulsed Dye Laser Therapy and Untreated Group
n=44 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face and the contralateral side of the face remained untreated, thus serving as an internal control.
Age, Categorical
<=18 years
1 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
43 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
25.41 years
STANDARD_DEVIATION 8.46 • n=99 Participants
Sex: Female, Male
Female
30 Participants
n=99 Participants
Sex: Female, Male
Male
14 Participants
n=99 Participants
Race/Ethnicity, Customized
Asian
5 participants
n=99 Participants
Race/Ethnicity, Customized
Black / African American
3 participants
n=99 Participants
Race/Ethnicity, Customized
Caucasian
30 participants
n=99 Participants
Race/Ethnicity, Customized
Hispanic, Latina
2 participants
n=99 Participants
Race/Ethnicity, Customized
Middle Eastern
2 participants
n=99 Participants
Race/Ethnicity, Customized
More than one race
1 participants
n=99 Participants
Race/Ethnicity, Customized
Unknown
1 participants
n=99 Participants
Region of Enrollment
United States
44 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Papule Acne Lesions at Week 10
Change from Baseline on Treated Side
-4.63 papule acne lesions
Interval -7.43 to -1.83
Change From Baseline in Papule Acne Lesions at Week 10
Change from Baseline on Untreated Side
-0.13 papule acne lesions
Interval -2.83 to 2.57

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Pustule Acne Lesions at Week 10
Change from Baseline on Treated Side
-1.80 pustule acne lesions
Interval -5.05 to 1.45
Change From Baseline in Pustule Acne Lesions at Week 10
Change from Baseline on Untreated Side
-1.20 pustule acne lesions
Interval -4.49 to 2.09

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Cysts at Week 10
Change from Baseline on Treated Side
0.10 cysts
Interval -0.35 to 0.55
Change From Baseline in Cysts at Week 10
Change from Baseline on Untreated Side
0.07 cysts
Interval -0.3 to 0.43

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Closed Comedones at Week 10
Change from Baseline on Treated Side
-5.07 closed comedones
Interval -10.53 to 0.4
Change From Baseline in Closed Comedones at Week 10
Change from Baseline on Untreated Side
-1.17 closed comedones
Interval -7.52 to 5.19

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Open Comedones at Week 10
Change from Baseline on Treated Side
-1.00 open comedones
Interval -6.37 to 4.37
Change From Baseline in Open Comedones at Week 10
Change from Baseline on Untreated Side
-0.63 open comedones
Interval -6.01 to 4.75

PRIMARY outcome

Timeframe: Baseline and Week 10

Outcome measures

Outcome measures
Measure
All Study Participants
n=25 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Erythematous Macules at Week 10
Change from Baseline on Treated Side
-1.88 erythematous macules
Interval -7.73 to 3.97
Change From Baseline in Erythematous Macules at Week 10
Change from Baseline on Untreated Side
1.28 erythematous macules
Interval -4.66 to 7.22

PRIMARY outcome

Timeframe: Baseline and Week 10

The Leeds scale is a 12-point ordinal photonumeric global acne severity scale where a rating of 1 denotes the mildest acne and a rating of 12 represents the most severe.

Outcome measures

Outcome measures
Measure
All Study Participants
n=30 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Acne Severity at Week 10
Change from Baseline on Treated Side
-0.90 units on a scale
Interval -1.3 to -0.5
Change From Baseline in Acne Severity at Week 10
Change from Baseline on Untreated Side
-0.30 units on a scale
Interval -0.65 to 0.05

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=29 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Papule Acne Lesions at Week 16
Change from Baseline on Treated Side
-1.79 papule acne lesions
Interval -5.98 to 2.39
Change From Baseline in Papule Acne Lesions at Week 16
Change from Baseline on Untreated Side
-0.97 papule acne lesions
Interval -4.32 to 2.39

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=29 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Pustule Acne Lesions at Week 16
Change from Baseline on Treated Side
-2.72 pustule acne lesions
Interval -6.65 to 1.2
Change From Baseline in Pustule Acne Lesions at Week 16
Change from Baseline on Untreated Side
-2.62 pustule acne lesions
Interval -6.25 to 1.01

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=29 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Cysts at Week 16
Change from Baseline on Treated Side
0.38 cysts
Interval -0.2 to 0.96
Change From Baseline in Cysts at Week 16
Change from Baseline on Untreated Side
0.24 cysts
Interval -0.33 to 0.82

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=29 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Closed Comedones at Week 16
Change from Baseline on Treated Side
-6.97 closed comedones
Interval -13.3 to -0.63
Change From Baseline in Closed Comedones at Week 16
Change from Baseline on Untreated Side
-4.07 closed comedones
Interval -9.12 to 0.98

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=29 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Open Comedones at Week 16
Change from Baseline on Treated Side
-4.79 open comedones
Interval -11.62 to 2.04
Change From Baseline in Open Comedones at Week 16
Change from Baseline on Untreated Side
-6.79 open comedones
Interval -13.88 to 0.29

SECONDARY outcome

Timeframe: Baseline and Week 16

Outcome measures

Outcome measures
Measure
All Study Participants
n=28 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Erythematous Macules at Week 16
Change from Baseline on Treated Side
-5.89 erythematous macules
Interval -12.12 to 0.34
Change From Baseline in Erythematous Macules at Week 16
Change from Baseline on Untreated Side
-2.50 erythematous macules
Interval -8.85 to 3.85

SECONDARY outcome

Timeframe: Baseline and Week 16

The Leeds scale is a 12-point ordinal photonumeric global acne severity scale where a rating of 1 denotes the mildest acne and a rating of 12 represents the most severe.

Outcome measures

Outcome measures
Measure
All Study Participants
n=27 Participants
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face while the contralateral side of the face remained untreated, thus serving as an internal control.
Change From Baseline in Acne Severity at Week 16
Change from Baseline on Treated Side
-1.07 units on a scale
Interval -1.69 to -0.45
Change From Baseline in Acne Severity at Week 16
Change from Baseline on Untreated Side
-0.52 units on a scale
Interval -1.07 to 0.04

Adverse Events

Treated Group Pulsed Dye Laser Therapy

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

Untreated Group Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Treated Group Pulsed Dye Laser Therapy
n=44 participants at risk
Patients were randomized to receive topical photosensitizer applications followed by pulsed dye laser therapy to one side of the face.
Untreated Group Control
n=44 participants at risk
The contralateral side of the face remained untreated, thus serving as an internal control.
Skin and subcutaneous tissue disorders
Mild Peeling
4.5%
2/44 • Number of events 2
0.00%
0/44
Skin and subcutaneous tissue disorders
Transient Postinflammatory Hyperpigmentation
4.5%
2/44 • Number of events 2
0.00%
0/44
Skin and subcutaneous tissue disorders
Blister
2.3%
1/44 • Number of events 1
0.00%
0/44

Additional Information

Dr. Jeffrey Orringer

University of Michigan Dept of Dermatology

Phone: 734-936-4075

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place